Company intelligence / Profile preview

IVF Japan Group

Osaka, Osaka Prefecture, Japan

Ownership: Private
Development stage: Other

Overview

IVF Japan Group offers the AUGMENT treatment, based on OvaScience’s EggPC cell technology, which is designed to enhance poor or compromised egg health, representing a scientific advance in improving success rates in IVF cycles. Positive clinician and patient feedback during preceptorship programs led to commercial rollout in Japan.

Therapeutic areas: Women's Health
Modalities: DeviceCell therapy
Industry: Non-Academic Healthcare

Partnerships

OvaScience (for commercial licensing and rollout of AUGMENT treatment in Japan)

Beyond the preview

Go deeper on IVF Japan Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVF Japan Group.

Explore the full profile